How often does APL relapse?

How often does APL relapse?

Despite this, relapse occurs in 5 to 10 percent of patients with APL and in 20 to 30 percent of those with high-risk APL (ie, presentation with a white blood cell count >10,000/microL and a platelet count <40,000/microL). Some of these relapses have occurred after more than five years in remission.

Can APL leukemia be cured?

Acute promyelocytic leukemia (APL) has become a curable disease by all-trans retinoic acid (ATRA)-based induction therapy followed by two or three courses of consolidation chemotherapy. Currently around 90\% of newly diagnosed patients with APL achieve complete remission (CR) and over 70\% of patients are curable.

What is the difference between APL and AML leukemia?

APL is a rare sub-type of acute myeloid leukaemia (AML). When you have APL, the bone marrow is not able to make enough normal blood cells. APL is treated in a very different way from other forms of AML, if a patient with APL is given standard treatment, there is a risk of serious problems with their clotting system.

What causes relapse in leukemia?

Relapses are relatively common in many types of leukemia. They may happen if the initial treatment doesn’t eliminate all cancer cells or if cancer cells become resistant to the treatment.

How do you treat relapsed acute promyelocytic leukemia?

Treatment of relapsed/advanced APL includes the use of arsenic trioxide (ATO), gemtuzumab ozogamicin, and hematopoietic stem cell transplantation. ATO is currently the most effective therapeutic agent in relapsed APL.

How long does APL treatment last?

Children with APL undergo one cycle of induction therapy, which lasts between 28 to 60 days. The length of the cycle depends on the response to treatment, which is evaluated by a bone marrow exam on Day 29.

How is promyelocytic leukemia treated?

The most important drugs for treating APL are non-chemo drugs called differentiating agents, like all-trans-retinoic acid (ATRA). Other treatments might include chemotherapy (chemo) and transfusions of platelets or other blood products. Treatment is typically divided into 3 phases: Induction (remission induction)

Why is DIC in acute promyelocytic leukemia?

In acute promyelocytic leukemia (APL), TF is secreted directly into the bloodstream by the membranes of the promyelocyte blast cells, which initiates the coagulation cascade causing DIC (Mc- Cance & Huether). An estimated 85\% of patients diagnosed with APL will develop DIC (Ezzone, 2000; Holmes-Gobel, 2000).

How is acute promyelocytic leukemia caused?

APL is caused by a chromosomal translocation (rearrangement of material) that occurs in some of the body’s cells during a person’s lifetime (a somatic mutation ). The translocation involves the fusion of two genes : the PML gene on chromosome 15 and the RARA gene on chromosome 17.

When does leukemia relapse?

Relapse of leukemia may occur several months to years after the initial remission; however the majority of relapses occur within two years of initial treatment. Refractory is a term that implies that patients have failed at least one treatment regimen after a relapse.

What happens relapse leukemia?

Patients who relapse in their marrow during or just after completing initial treatment may benefit from a stem cell transplant. Patients who relapse six months or more after initial treatment can often be re-treated with more intensive chemotherapy without a transplant. Relapses most often occur in the bone marrow.

Is acute promyelocytic leukemia curable?

l Because of advances in diagnosis and treatment of this disease, APL is now considered the most curable form of adult leukemia. Cure rates of 90 percent have been reported from centers specializing in APL treatment. l A common symptom of APL is bleeding.

Why is rapid diagnosis and treatment of acute promyelocytic leukemia (APL) important?

Prompt diagnosis and treatment of acute promyelocytic leukemia (APL), the M3 subtype of acute myeloid leukemia (AML), is very important because patients with APL can quickly develop life-threatening blood-clotting or bleeding problems if not treated.

How long does maintenance therapy for acute myeloid leukemia (APL) last?

Maintenance therapy is typically given for about a year. Treatment for APL that doesn’t go away or that comes back after initial treatment is discussed in If Acute Myeloid Leukemia (AML) Doesn’t Respond or Comes Back After Treatment.

Are ATRA and ATO alone sufficient to treat high-risk acute promyelocytic leukemia (APL)?

ATRA and ATO alone are insufficient for the treatment of high-risk APL, and there seems to be a benefit from substantial cytoreduction early during induction. Cytotoxic chemotherapy with idarubicin was added to a combination of corticosteroids, ATRA, and ATO to treat 23 high-risk patients in the Australian APML4 study.